Clinical Trial

Perioperative Colchicine for TKA

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, randomized, double-blinded, placebo-controlled study of the drug colchicine in the acute postoperative period for patients who are undergoing a total knee arthroplasty (TKA). Patients aged 18 years or older who are undergoing TKA will be invited to participate in the study. The primary endpoint of this study is to determine if colchicine, an anti-inflammatory medication commonly used for gout attacks, will decrease the postoperative pain of patients undergoing elective TKA.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-14; most recent amendment 2025-08-15.
Trial Details
NCT Number NCT06936709
Lead Sponsor Geisinger Clinic
Collaborators: St. Luke's Hospital, Kansas City, Missouri
Conditions Osteoarthritis of Knee, Recovery Following Primary Total Knee Arthroplasty, Perioperative Pain Control
Enrollment 75 participants
Start Date 2025-12-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-17